Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generics Bulletin Editor’s Picks For Q2 2022

Highlights Across The Off-Patent Sector From April To June 2022

Executive Summary

Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.

You may also be interested in...

Sandoz’s High-Concentration Humira Biosimilar Lands On FDA’s Desk

Sandoz has named its three most promising upcoming biosimilar launches, ahead of filing its proposed high-concentration version of adalimumab with the US Food and Drug Administration.

EU Health Emergency Response Authority Calls On Off-Patent Sector

The director-general of the European Commission’s recently-formed Health Emergency Response Authority addressed delegates to off-patent association Medicines for Europe’s 2022 annual conference, noting that it was preparing a report for post-summer as the HERA assessed its priorities.

EMA Firms Up February 2025 Date For Shortages Monitoring Platform

During the recent Medicines for Europe 2022 annual conference, held in Sitges, Barcelona, the EMA’s head of supply and availability of medicines and devices, Monica Dias, provided delegates with a detailed update on plans to implement the agency’s major shortages monitoring platform by early 2025.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts